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Results: The frequencies of which the small, medium and 
large size plans were used over the (total of 600) fractions 
were similar; plans were used at a median of 9, 9.5 and 10 
fractions respectively. The median volume ratio of PTV-ART 
vs. non-ART across the treatment course was 0.70 (range: 
0.46-0.89). The median rectal volume receiving 50 Gy or 
more was 5% (range: 0-41%), compared to 17% (range: 0-62%) 
if the patients had been treated with standard, non-adaptive 
RT (Fig 1). For the bowel cavity, the median volume receiving 
more than 45 Gy was 392 cm3 (range: 84-625 cm3), compared 
to 487 cm3 (range: 126-710 cm3) if not treated with 
adaptation (Fig 1). 
Conclusions: Daily adaptive plan selection in RT of bladder 
cancer results in a considerable normal tissue sparing, which 
is expected to reduce the risk of gastro-intestinal morbidity. 
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Medical physicists contribute to maintaining and improving 
quality, safety and cost-effectiveness of healthcare services 
through patient-oriented activities requiring expert action, 
involvement or advice regarding the specification, selection, 
acceptance testing, commissioning, quality assurance/control 
and optimised clinical use of medical radiological devices. 
Medical physicists working in a clinical environment are 
healthcare professionals and those at the highest level (level 
8 on the European qualifications framework)are Medical 
Physics Experts(MPEs) competent to practice independently 
in one or more of the subfields (specialties) of medical 
physics; in this way the MPE has the capabilities to tackle 
clinical problems through strategic multidisciplinary 
approaches.  
Today the multidisciplinary approach with medical physicists 
in the clinical environment together with those in the 
commercial industry as well as university research areas is 
mandatory where dosimetry, dosimetric calculation and 
medical imaging for planning and verification needs to be 
approached with a number of different competences. 
Collaboration on clinical research projects between 
commercial partners and medical physicists/MPE should 
therefore be encouraged at all levels. 
Academic partners have the capabilities to develop new 
applications of physics in medicine (linear accelerators, new 
detectors, Monte Carlo simulations, etc.) and have the 
competences required to support such developments. The 
experience derived from protosyncrotony and ion and 
particle accelerator developments in particle research has 
provided fundamental experience to understand what the 
correct approach needs to be to tackle the clinical 
applications.  
Companies have the role to develop hardware and software 
devices for radiotherapy but need medical physics 
competences for testing and optimization "on the field". Many 
advanced medical physics departments are "beta-site" for 
different applications. Pre-release software for treatment 
planning, new treatment modalities, image processing and 
registration technique for Adaptive planning , integrated 
MRI/linear accelerator and high intensity focused ultrasound 
(HIFU) in oncology therapy are typical examples where a 
multidisciplinary approach is essential. A PACS solution for 
radiotherapy is another examples where medical physicists 
are able to define the functional differences between the 
PACS required for radiotherapy compared with the 
requirements for conventional radiology PACS.  
New software for image integration and registration 
techniques must first be validated in clinical practice and the 
multidisciplinary medical physics department is an essential 
partner for companies to create optimized protocols for 
clinical use. 
Finally the medical physicist/MPE is frequently involved in 
training activities  and these experts can also be used to 
inform companies on their development profiles. 
The use of webinar will provide further opportunities for the 
cooperation and training for all the actors involved in 
radiotherapy. 
In conclusion, in order to ensure  that the quality of patient 
treatments is maintained and further improved while  the 
risk of errors is reduced it is necessary that all these 
activities are to be carried out in the clinical working 
environment. In addition many of these activities require 
further development and improvement  within a research 
environment  parallel to the clinical work. 
However, staff often have to carry out research and 
development outside normal working hours due to lack of 
time. This situation is not sustainable and could finally result 
in unsafe patient treatments. It must be realized that 
medical physics departments should have at least an 
additional 0.3 whole time equivalent staffing complement 
(ref. European Guidelines on Medical Physics Expert (Annex 
2)) to carry out these important research and development 
activities. 
References: European Guidelines on Medical Physics Expert, 
Annex 2, Radiation Report No174, European Commission, 
2014  
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In the past decade the introduction of new technologies such 
as IMRT has given a strong boost to medical physics and the 
field of radiation oncology in the US. In the period from 2003 
until 2009 alone, the expenditure for radiation oncology has 
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almost tripled, which is the largest growth rate of any 
medical specialty in that period. This development has 
strengthened the standing of medical physics and radiation 
oncology in the hospitals. However, it has also been 
recognized that the growth in expenditure has not come with 
an increase in patient volume or corresponding outcome 
improvements. More recently the trend has reversed due in 
part to the overall economical situation and the healthcare 
reform. Cutting cost is the new theme. The research in 
medical physics has been hit particularly hard by this 
development. The budget and time for research is being cut. 
Funding from government agencies is increasingly harder to 
get. The trend to more "professionalism" in medical physics 
with mandatory physics residencies has shifted the focus 
further away from research. 
In this presentation we will report on our efforts within the 
American Association of Physicists in Medicine (AAPM) 
Working Group FUTURE (FUTURE of Research and Academic 
Training) to put medical physics research back on the map. 
WG FUTURE activities include the definition of research 
activity roadmaps, organization of "Expanding Horizons" 
meetings to open doors for medical physics research outside 
of radiation oncology, support of students aspiring a research 
career in medical physics, and reaching out to similar 
activities elsewhere in the world.  
We will also report on our own challenges of developing and 
maintaining a vibrant research environment in academic 
medical physics (at the University of Madison, Wisconsin) at 
in a hospital environment (Massachusetts General Hospital).  
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I would like to start by adding "small" and "clinical" to the 
title. It would then read research in a small clinical Medical 
Physics Department. Two things to define: research and 
small. Let’s start with research. Research is “serious study of 
a subject that is intended to discover new facts or test new 
ideas”. Small applied to a Medial Physics Department is more 
difficult to define but everybody would agree that a staff of 6 
physicists, 6 RTT, 3 residents and 1 secretary to give service 
to Radiation Oncology, Nuclear Medicine, Imaging and 
Radiation Protection is not BIG. This describes the 
department in which I am working in. Now, the question: Can 
such a Department do any Research? And if so how this can 
happen? Four clues:  
1. Optimize QA to get the time.Time is needed to think, to 
get inspired in order to choose the subject of your research. 
2. Don’t wait to see if you become BIG to start. It may never 
happen. 
3. Link to other departments in the hospital, link to other 
Medical Physics departments in your city, departments at the 
Universities. This will enlarge your human resources and you 
will increase expertise in your group and also have different 
and interesting angles to your research topic. 
4. Inspiration. Think outside the box. Take risks! 
By doing this I think that you can study a subject and discover 
new facts or test new ideas. This is RESEARCH. It requires 
effort and enthusiasm, research is fun. Being small does not 
mean that you can’t think BIG.  
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The number of facilities proton therapy is increasing around 
the world. The benefit of delivering radiation treatment with 
protons as compared to photons is the reduced integral dose 
due to the protons stopping inside the patient and delivering 
a high dose at the end of their range. This leads to highly 
conformal dose distributions with sharp dose gradients, both 
laterally as well as at the distal end of a proton treatment 
field. The distal high dose gradients make accurate dose 
calculations for proton therapy even more important than for 
photon therapy. A slight underestimation in proton range can 
lead to unirradiated sections of the target region.  
Clinical dose calculations are generally performed using 
analytical algorithms, often referred to as pencil-beam 
algorithms, which propagate protons through the patient 
geometry. Each field is composed of ‘pencils’ which are 
separated into a central axis part combined with a Gaussian 
fluence map to account for the lateral beam spread. The 
main advantage of this approach is its computational speed. 
More accurate dose calculation algorithms such as Monte 
Carlo (MC) simulations are available but have not yet 
translated into clinical routine for proton therapy treatment 
planning due to lengthly calculation times. MC simulations 
are, however, frequently used to estimate the accuracy of 
analytical dose calculation algorithms.  
Analytical algorithms generally fail to describe the effects of 
multiple Coulomb-scattering of protons. These effects are 
particularly important along high-density interfaces along the 
treatment field direction. Incorrect modeling of scattering 
can result in distortions of the delivered dose distributions. 
This can effect both the range of the proton field as well as 
the delivered dose distribution. Both effects will be discussed 
through comparisons between MC simulations and analytical 
dose calculations. We investigated the validity of range 
margins to compensate for range uncertainties and the 
clinical impact of dose calculation approximations. 
In a site-specific analysis looking at 10-24 patients for 7 
treatment sites, we find that for liver, prostate and whole 
brain fields a reduction of currently used uncertainty margins 
is feasible even without introducing MC dose calculations. 
Accounting for uncertainties from dose calculation algorithms 
we recommend a reduction of these margins to 2.8% + 1.2 
mm for liver and prostate treatments and 3.1% + 1.2 mm for 
whole brain treatments, respectively. For some breast, lung 
and head & neck patients dose calculations current range 
margins are found to be insufficient, at least if used 
generically. We recommend a generic margin of 6.3% + 1.2 
mm for breast, lung and head & neck treatments if no case 
specific adjustments are applied. Thus, currently used 
generic range uncertainty margins in proton therapy should 
be redefined in a site-specific manner and complex 
geometries may require a field specific adjustment.  
For a dosimetric analysis of clinical used properties in a study 
containing 10 patients per site for 5 treatment sites, we find 
that target doses obtained with analytical dose calculation 
methods are, on average, 1-2% higher compared to those 
calculated with MC simulations. Both calculation methods 
agree within 5% for the mean dose, and the dose values 
covering 95%, 50% and 2% of the target volume. A γ-index 
